vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and LQR House Inc. (YHC). Click either name above to swap in a different company.
LQR House Inc. is the larger business by last-quarter revenue ($299.7K vs $169.0K, roughly 1.8× Aligos Therapeutics, Inc.). On growth, LQR House Inc. posted the faster year-over-year revenue change (-64.2% vs -72.1%). Over the past eight quarters, LQR House Inc.'s revenue compounded faster (-21.1% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
LQR House Inc. is a US-based alcohol beverage e-commerce and distribution company. It offers a broad portfolio of spirits, wine, and beer, operating two core segments: direct-to-consumer retail for individuals and wholesale distribution for business clients across the United States.
ALGS vs YHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $299.7K |
| Net Profit | — | $-4.1M |
| Gross Margin | — | 17.8% |
| Operating Margin | — | -1000.3% |
| Net Margin | — | -1368.7% |
| Revenue YoY | -72.1% | -64.2% |
| Net Profit YoY | 75.8% | 72.2% |
| EPS (diluted) | — | $2.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $299.7K | ||
| Q3 25 | $741.0K | $337.3K | ||
| Q2 25 | $965.0K | $498.5K | ||
| Q1 25 | $311.0K | $429.3K | ||
| Q4 24 | $606.0K | $838.2K | ||
| Q3 24 | $1.3M | $624.5K | ||
| Q2 24 | $1.1M | $557.9K | ||
| Q1 24 | $694.0K | $481.1K |
| Q4 25 | — | $-4.1M | ||
| Q3 25 | $-31.5M | $-16.8M | ||
| Q2 25 | $-15.9M | $-2.2M | ||
| Q1 25 | $43.1M | $-2.4M | ||
| Q4 24 | $-82.2M | $-14.8M | ||
| Q3 24 | $-19.3M | $-3.4M | ||
| Q2 24 | $5.1M | $-2.2M | ||
| Q1 24 | $-34.9M | $-2.4M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | — | 17.0% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | -9.9% | ||
| Q2 24 | — | -27.3% | ||
| Q1 24 | — | -16.5% |
| Q4 25 | — | -1000.3% | ||
| Q3 25 | -3827.4% | -1134.8% | ||
| Q2 25 | -1924.0% | -442.1% | ||
| Q1 25 | -6187.5% | -559.0% | ||
| Q4 24 | -3393.2% | -1221.3% | ||
| Q3 24 | -1610.5% | -561.1% | ||
| Q2 24 | -2489.5% | -407.7% | ||
| Q1 24 | -3176.7% | -513.9% |
| Q4 25 | — | -1368.7% | ||
| Q3 25 | -4256.0% | -4989.5% | ||
| Q2 25 | -1643.8% | -441.8% | ||
| Q1 25 | 13854.7% | -556.6% | ||
| Q4 24 | -13556.1% | -1760.2% | ||
| Q3 24 | -1540.7% | -538.6% | ||
| Q2 24 | 477.0% | -396.0% | ||
| Q1 24 | -5023.5% | -504.6% |
| Q4 25 | — | $2.94 | ||
| Q3 25 | $-3.04 | $-1.50 | ||
| Q2 25 | $-1.53 | $-1.10 | ||
| Q1 25 | $-2.11 | $-3.85 | ||
| Q4 24 | $-13.10 | $-88.71 | ||
| Q3 24 | $-3.07 | $-21.84 | ||
| Q2 24 | $0.81 | $-15.49 | ||
| Q1 24 | $-5.58 | $-18.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $29.3M |
| Total Assets | $88.5M | $31.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | $10.0M | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | $5.4M | ||
| Q3 24 | $74.9M | $3.7M | ||
| Q2 24 | $94.5M | $4.6M | ||
| Q1 24 | $112.7M | $4.0M |
| Q4 25 | $53.5M | $29.3M | ||
| Q3 25 | $71.8M | $27.4M | ||
| Q2 25 | $101.9M | $12.2M | ||
| Q1 25 | $116.4M | $7.3M | ||
| Q4 24 | $-29.0M | $-518.0K | ||
| Q3 24 | $50.1M | $9.1M | ||
| Q2 24 | $67.2M | $11.7M | ||
| Q1 24 | $59.8M | $12.4M |
| Q4 25 | $88.5M | $31.2M | ||
| Q3 25 | $109.8M | $35.0M | ||
| Q2 25 | $134.7M | $14.4M | ||
| Q1 25 | $150.7M | $9.6M | ||
| Q4 24 | $70.1M | $6.9M | ||
| Q3 24 | $88.4M | $9.8M | ||
| Q2 24 | $108.8M | $12.2M | ||
| Q1 24 | $127.9M | $12.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-14.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-14.3M | ||
| Q3 25 | $-24.3M | $-11.3M | ||
| Q2 25 | $-15.5M | $-1.6M | ||
| Q1 25 | $-20.9M | $-6.6M | ||
| Q4 24 | $-18.4M | $-3.1M | ||
| Q3 24 | $-20.1M | $-1.0M | ||
| Q2 24 | $-19.5M | $-1.2M | ||
| Q1 24 | $-22.7M | $-1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -287.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
